Infection and Drug Resistance (Jun 2022)

Resistant-Associated Substitutions Do Not Affect HCV RNA and HCV Core Antigen Clearance During Direct-Acting Antiviral Agent Treatment in a Real-World Setting

  • Chen H,
  • Liu J,
  • Kang Q,
  • Luo H,
  • Tan N,
  • Pan J,
  • Yang Y,
  • Yu M,
  • Liu D,
  • Xi H,
  • Han Y,
  • Cheng R,
  • Yu Y,
  • Xu X

Journal volume & issue
Vol. Volume 15
pp. 3373 – 3380

Abstract

Read online

Hongyu Chen,1 Jianxiang Liu,2 Qian Kang,1 Hao Luo,1 Ning Tan,1 Jiali Pan,1 Yuqing Yang,1 Min Yu,1 Dan Liu,1 Hongli Xi,1 Yifan Han,1 Ran Cheng,1 Yanyan Yu,1 Xiaoyuan Xu1 1Departments of Infectious Diseases, Peking University First Hospital, Beijing, People’s Republic of China; 2Department of Gastroenterology, Peking University First Hospital, Beijing, People’s Republic of ChinaCorrespondence: Xiaoyuan Xu; Yanyan Yu, Email [email protected]; [email protected]: Since oral direct-acting antiviral agents (DAAs) became available, the global hepatitis C treatment situation has undergone tremendous changes. However there are still many issues worthy of attention in treatment.Methods: We selected 53 HCV-infected patients who were treated and followed up in the Peking University First Hospital from December 2017 to January 2021 to detect the RASs in HCV. Pearson correlation analysis was used to analyze HCV RNA and HCV cAg, the Fisher exact test and chi-square test was used to compare the effects of RASs on the rate of decline of HCV RNA and HCV core antigen (cAg) during DAA treatment.Results: The RASs and its prevalence on the NS3 are mainly Y56F 2.56% (1/39), Q80K 23.08% (9/39), S122G 71.79% (28/39), and V170I 38.46% (15/39). On the NS5A were R30Q 10.53% (4/38), P32A 5.26% (2/38), P58S 2.63% (1/39), and Y93H 21.05% (8/38). On NS5B were C316N 71.05% (27/38), C451H 2.63% (1/38), and I585C 2.63% (1/38). There was no significant correlation between the RASs (Y93H, V179I, Q80K, S122G, C316N) and HCV genotype (p > 0.05). The baseline serum HCV RNA and HCV cAg had a significant medium-degree correlation (r = 0.601, p = 0.002). After 1 week of DAA treatment was weak correlation (r = 0.413, p = 0.032). Q80K, S122G, V170I, Y93H, and C316N had no effect on the clearance of HCV RNA and HCV cAg within the first week of DAA treatment (p> 0.05).Conclusion: The HCV genotype may have a limited impact on the presence of the five RASs (Y93H, V179I, Q80K, S122G, and C316N) as shown in this study. HCV RNA and HCV cAg have a correlation, especially at baseline is the highest; the appearance of some RASs has no effect on DAA treatment in most chronic hepatitis C patients.Keywords: hepatitis C virus, chronic hepatitis C, drug resistance, sequencing

Keywords